Abstract
Breast cancer is still the leading cause of cancer deaths among women worldwide, and new therapies to treat this dangerous disease are desperately needed. The serendipitously found anticancer drug cisplatin and its second-generation congener carboplatin appear to be promising drug systems for the treatment of breast tumors, in particular of multidrug resistant and highly aggressive triplenegative subtypes. In the wake of these platinum drugs, complexes of the coinage metals copper, silver, and gold were developed that showed enhanced selectivity for breast cancer while causing fewer and weaker side-effects. This review takes stock of the latest developments in the field of coinage metal anticancer drugs with an emphasis on their biological and mechanistic aspects. Pertinent literature is covered up to 2012.
Keywords: Copper complexes, silver complexes, gold complexes, anticancer drugs, breast cancer, cancer deaths, serendipitously, congener carboplatin, breast tumors, platinum drugs
Current Medicinal Chemistry
Title:Coinage Metal Complexes Against Breast Cancer
Volume: 19 Issue: 23
Author(s): B. Biersack, A. Ahmad, F. H. Sarkar and R. Schobert
Affiliation:
Keywords: Copper complexes, silver complexes, gold complexes, anticancer drugs, breast cancer, cancer deaths, serendipitously, congener carboplatin, breast tumors, platinum drugs
Abstract: Breast cancer is still the leading cause of cancer deaths among women worldwide, and new therapies to treat this dangerous disease are desperately needed. The serendipitously found anticancer drug cisplatin and its second-generation congener carboplatin appear to be promising drug systems for the treatment of breast tumors, in particular of multidrug resistant and highly aggressive triplenegative subtypes. In the wake of these platinum drugs, complexes of the coinage metals copper, silver, and gold were developed that showed enhanced selectivity for breast cancer while causing fewer and weaker side-effects. This review takes stock of the latest developments in the field of coinage metal anticancer drugs with an emphasis on their biological and mechanistic aspects. Pertinent literature is covered up to 2012.
Export Options
About this article
Cite this article as:
Biersack B., Ahmad A., H. Sarkar F. and Schobert R., Coinage Metal Complexes Against Breast Cancer, Current Medicinal Chemistry 2012; 19 (23) . https://dx.doi.org/10.2174/092986712802002482
DOI https://dx.doi.org/10.2174/092986712802002482 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bone Morphogenetic Proteins and its Receptors; Therapeutic Targets in Cancer Progression and Bone Metastasis?
Current Pharmaceutical Design Design, Synthesis, and Preliminary Bioactivity Evaluation of 2,7-Substituted Carbazole Derivatives as Potent Autotaxin Inhibitors and Antitumor Agents†
Anti-Cancer Agents in Medicinal Chemistry Passive Targeting of Cyclophosphamide-Loaded Carbonate Apatite Nanoparticles to Liver Impedes Breast Tumor Growth in a Syngeneic Model
Current Pharmaceutical Design Suppression of TLR Signaling by Targeting TIR domain-Containing Proteins
Current Protein & Peptide Science Pharmacogenetics of Irinotecan Disposition and Toxicity: A Review
Current Clinical Pharmacology Between Bench and Bed Side: PI3K Inhibitors
Current Molecular Pharmacology The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs
Current Pharmaceutical Design CXCR4-targeted Nanoparticles Reduce Cell Viability, Induce Apoptosis and Inhibit SDF-1α Induced BT-549-Luc Cell Migration In Vitro
Current Drug Delivery Molecular Dynamics Guided Receptor Independent 4D QSAR Studies of Substituted Coumarins as Anticancer Agents
Current Computer-Aided Drug Design In Vivo Imaging of Oligonucleotides with Nuclear Tomography
Current Drug Targets Molecular Replacement in Cancer Therapy: Reversing Cancer Metabolic and Mitochondrial Dysfunction, Fatigue and the Adverse Effects of Cancer Therapy
Current Cancer Therapy Reviews Nuclear Medicine: from Photons to Physiology
Current Pharmaceutical Design Nanonetworks in Biomedical Applications
Current Drug Targets T Lymphocytes as Targets of Statins: Molecular Mechanisms and Therapeutic Perspectives
Inflammation & Allergy - Drug Targets (Discontinued) Targeting the Immune System in Cancer
Current Pharmaceutical Biotechnology Clinical Use of Neurophysiological Biomarkers and Self-Assessment Scales to Predict and Monitor Treatment Response for Psychotic and Affective Disorders
Current Pharmaceutical Design Comparative Genomic Hybridization: A Valuable Tool for Genome-Scale Analysis of Rodent Cancer Models
Current Genomics Radionuclide Therapy of Cancer with Radiolabeled Antibodies
Anti-Cancer Agents in Medicinal Chemistry Thiomers, Mucoadhesion and Oral Delivery of Biomacromolecules
Current Drug Therapy Editorial [Hot Topic: Anticancer Platinum Complexes - State of the Art and Future Prospects (Guest Editor: Markus Galanski)]
Anti-Cancer Agents in Medicinal Chemistry